1. Home
  2. BMY
  3. BMY News

Latest Bristol-Myers Squibb Company (BMY) News on August 9, 2025

The Strong Earnings Posted By Bristol-Myers Squibb (NYSE:BMY) Are A Good Indication Of The Strength Of The Business
BMY

Simply Wall St.

2 days ago

The Strong Earnings Posted By Bristol-Myers Squibb (NYSE:BMY) Are A Good Indication Of The Strength Of The Business

BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
BMY

Zacks

3 days ago

BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?

5% Yields Are Hard to Find. Here Are 4 Dividend Stocks You Can Count On.
BMY

Barrons.com

3 days ago

5% Yields Are Hard to Find. Here Are 4 Dividend Stocks You Can Count On.

Pfizer Pops Despite Looming Pharma Tariffs
BMY

The Daily Upside

3 days ago

Pfizer Pops Despite Looming Pharma Tariffs

Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth
BMY

Zacks

4 days ago

Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth

Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
BMY

Zacks

4 days ago

Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
BMY

Zacks

4 days ago

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO
BMY

BioPharma Dive

4 days ago

Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO

BMY

MT Newswires

4 days ago

Daiwa Securities Downgrades Bristol-Myers Squibb to Neutral From Outperform, Adjusts PT to $42 From $60

BMY

MT Newswires

4 days ago

Bristol-Myers Squibb Says FDA Grants Priority Review to Cancer Drug

Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
BMY

Business Wire

5 days ago

Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
BMY

Zacks

5 days ago

Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?

BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped.
BMY

Barrons.com

5 days ago

BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped.

J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
BMY

Zacks

5 days ago

J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
BMY

CNW Group

5 days ago

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
BMY

GlobeNewswire

5 days ago

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time
BMY

The Wall Street Journal

6 days ago

Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time

Bristol-Myers Squibb Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
BMY

Simply Wall St.

7 days ago

Bristol-Myers Squibb Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

BMY

Morningstar Research

7 days ago

Analyst Report: Bristol-Myers Squibb Company

BMY

MT Newswires

8 days ago

UBS Adjusts Price Target on Bristol-Myers Squibb to $46 From $52, Maintains Neutral Rating

BMY

MT Newswires

8 days ago

BMO Capital Adjusts Price Target on Bristol-Myers Squibb to $47 From $53, Maintains Market Perform Rating

BMY

MT Newswires

8 days ago

Citigroup Adjusts Price Target on Bristol-Myers Squibb to $47 From $51, Maintains Neutral Rating

BMY

MT Newswires

8 days ago

Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $51 From $56, Maintains Neutral Rating

BMY

MT Newswires

8 days ago

Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Maintains Outperform Rating

BMY

MT Newswires

8 days ago

JPMorgan Cuts Price Target on Bristol-Myers Squibb to $65 From $67, Maintains Overweight Rating

Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?
BMY

Simply Wall St.

8 days ago

Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?

Stock Index Futures Plunge on Trump’s Tariffs & A Weak US Jobs Report
BMY

Barchart

8 days ago

Stock Index Futures Plunge on Trump’s Tariffs & A Weak US Jobs Report

BMY

Morningstar Research

8 days ago

Analyst Report: Bristol-Myers Squibb Company

Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?
BMY

Zacks

10 days ago

Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?

BMY

Morningstar Research

10 days ago

Analyst Report: ConvaTec Group PLC

Bristol-Myers Squibb (BMY) Q2 Earnings: What To Expect
BMY

StockStory

10 days ago

Bristol-Myers Squibb (BMY) Q2 Earnings: What To Expect

Why Investors View Bristol‑Myers Squibb (BMY) as a Safe Dividend Stock for Income
BMY

Insider Monkey

11 days ago

Why Investors View Bristol‑Myers Squibb (BMY) as a Safe Dividend Stock for Income

Merck Earnings Beat Analyst Estimates. Why the Stock Is Dropping.
BMY

Barrons.com

11 days ago

Merck Earnings Beat Analyst Estimates. Why the Stock Is Dropping.

EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
BMY

Zacks

11 days ago

EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues

BMY

MT Newswires

11 days ago

Piper Sandler Adjusts Price Target on Bristol-Myers Squibb to $64 From $66, Maintains Overweight Rating

Bain leads $300M investment in startup built on Bristol Myers immune drugs
BMY

BioPharma Dive

11 days ago

Bain leads $300M investment in startup built on Bristol Myers immune drugs

Bristol Myers, Bain Capital form new company to develop immunology drugs
BMY

Reuters

11 days ago

Bristol Myers, Bain Capital form new company to develop immunology drugs

Bristol Myers Squibb and Bain Capital Form New Immunology Company
BMY

The Wall Street Journal

12 days ago

Bristol Myers Squibb and Bain Capital Form New Immunology Company

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
BMY

Business Wire

12 days ago

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings
BMY

Barchart

12 days ago

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings

Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.
BMY

Barrons.com

12 days ago

Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.

Goldman Sachs Maintains a Hold on Bristol-Myers Squibb (BMY)
BMY

Insider Monkey

12 days ago

Goldman Sachs Maintains a Hold on Bristol-Myers Squibb (BMY)

Biotech Is Booming, and This Undervalued REIT Stands to Gain
BMY

Motley Fool

15 days ago

Biotech Is Booming, and This Undervalued REIT Stands to Gain

Myeloproliferative Disorder Treatment Market Insights, Competitive Landscape, and Forecast Report 2025-2032 Featuring Novartis, Incyte, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia
BMY

GlobeNewswire

15 days ago

Myeloproliferative Disorder Treatment Market Insights, Competitive Landscape, and Forecast Report 2025-2032 Featuring Novartis, Incyte, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia

BMY

MT Newswires

15 days ago

Bristol-Myers Squibb Names Cristian Massacesi as Chief Medical Officer

Bristol Myers shuffles its executive ranks with new CMO
BMY

BioPharma Dive

15 days ago

Bristol Myers shuffles its executive ranks with new CMO

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development
BMY

Business Wire

15 days ago

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

2 Cash-Producing Stocks to Keep an Eye On and 1 We Find Risky
BMY

StockStory

15 days ago

2 Cash-Producing Stocks to Keep an Eye On and 1 We Find Risky

Roche Weighs Selling Drugs Directly to Patients in Bid to Lower U.S. Prices
BMY

The Wall Street Journal

16 days ago

Roche Weighs Selling Drugs Directly to Patients in Bid to Lower U.S. Prices

Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
BMY

Zacks

16 days ago

Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?

Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
BMY

Zacks

16 days ago

Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for

BMY

MT Newswires

16 days ago

Bausch Health Appoints Two Members to Board

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
BMY

ACCESS Newswire

16 days ago

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

ModelOp Transforms Enterprise AI Governance with Launch of the First Agentic AI Chat Interface and Controls for Agentic AI
BMY

GlobeNewswire

16 days ago

ModelOp Transforms Enterprise AI Governance with Launch of the First Agentic AI Chat Interface and Controls for Agentic AI

How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab
BMY

Pharma Voice

16 days ago

How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab

Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks
BMY

StockStory

16 days ago

Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks

Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
BMY

Zacks

17 days ago

Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?

Jim Cramer on Bristol-Myers: “Never Seen it This Cheap”
BMY

Insider Monkey

17 days ago

Jim Cramer on Bristol-Myers: “Never Seen it This Cheap”

Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?
BMY

Zacks

17 days ago

Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?

Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know
BMY

Zacks

18 days ago

Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know

Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
BMY

Investor's Business Daily

18 days ago

Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock

JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
BMY

Zacks

18 days ago

JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra

Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment
BMY

Barrons.com

18 days ago

Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment

Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?
BMY

StockStory

18 days ago

Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?

EdgeOne Medical Announces Appointment of Michael Denzer as VP, Client Relations to Further Elevate Product Innovation and Client Partnerships
BMY

Business Wire

19 days ago

EdgeOne Medical Announces Appointment of Michael Denzer as VP, Client Relations to Further Elevate Product Innovation and Client Partnerships

Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
BMY

Zacks

19 days ago

Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
BMY

Zacks

19 days ago

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer
BMY

Insider Monkey

19 days ago

Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer

BMY

MT Newswires

19 days ago

Bristol-Myers Squibb Says Its Supplemental Application for Psoriatic Arthritis Treatment Accepted for Review

Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
BMY

Business Wire

19 days ago

Bristol Myers Squibb’s Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

BMS’ Phase III trial of Reblozyl misses primary endpoint
BMY

Clinical Trials Arena

19 days ago

BMS’ Phase III trial of Reblozyl misses primary endpoint

Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025
BMY

Insider Monkey

21 days ago

Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025

Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT
BMY

Insider Monkey

22 days ago

Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT

Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program
BMY

Insider Monkey

22 days ago

Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program

Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial
BMY

Benzinga

22 days ago

Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial

With 82% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing
BMY

Simply Wall St.

22 days ago

With 82% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
BMY

Zacks

22 days ago

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

BMY

MT Newswires

22 days ago

Bristol Myers Squibb's Reblozyl Trial for Anemia Fails to Meet Primary Endpoint

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
BMY

Business Wire

22 days ago

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

Stocks to Watch Recap: TSMC, United Airlines, GE Aerospace, Lucid
BMY

The Wall Street Journal

23 days ago

Stocks to Watch Recap: TSMC, United Airlines, GE Aerospace, Lucid

BMY

MT Newswires

23 days ago

Sector Update: Health Care Stocks Fall Late Afternoon

BMY

MT Newswires

23 days ago

Sector Update: Health Care

BMY

Investing.com

23 days ago

GSK stock falls after FDA panel rejects blood cancer drug Blenrep

Ryan Richardson Departs BioNTech (BNTX), A Pillar In US$1 Billion Capital Raises
BMY

Simply Wall St.

23 days ago

Ryan Richardson Departs BioNTech (BNTX), A Pillar In US$1 Billion Capital Raises

Pfizer (PFE) Expands Patient Access With Eliquis (Apixaban) Direct Purchase Program
BMY

Simply Wall St.

23 days ago

Pfizer (PFE) Expands Patient Access With Eliquis (Apixaban) Direct Purchase Program

BMY

MT Newswires

23 days ago

Bristol-Myers Squibb, Pfizer Alliance Launch Direct-to-Patient Stroke Drug Purchase Program

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients
BMY

Reuters

23 days ago

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
BMY

Business Wire

23 days ago

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option

Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount
BMY

The Wall Street Journal

23 days ago

Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount

Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
BMY

Zacks

24 days ago

Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

Will Increased Expenses Affect Bristol Myers' Performance?
BMY

Zacks

24 days ago

Will Increased Expenses Affect Bristol Myers' Performance?

Winn CIPP Welcomes Cohort 4 Medical Students Focused on Connecting Communities to Clinical Research
BMY

ACCESS Newswire

a month ago

Winn CIPP Welcomes Cohort 4 Medical Students Focused on Connecting Communities to Clinical Research

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board
BMY

Business Wire

a month ago

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board

3 Top Dividend Stocks to Maximize Your Retirement Income
BMY

Zacks

a month ago

3 Top Dividend Stocks to Maximize Your Retirement Income

Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
BMY

Zacks

a month ago

Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?

Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar?
BMY

Zacks

a month ago

Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar?

What to Expect From Bristol-Myers Squibb's Q2 2025 Earnings Report
BMY

Barchart

a month ago

What to Expect From Bristol-Myers Squibb's Q2 2025 Earnings Report

Can Bristol-Myers Squibb Company (BMY) Provide Stable Long-Term Income?
BMY

Insider Monkey

a month ago

Can Bristol-Myers Squibb Company (BMY) Provide Stable Long-Term Income?

FDA willing to trade faster drug reviews for lower prices, Bloomberg reports
BMY

TipRanks

a month ago

FDA willing to trade faster drug reviews for lower prices, Bloomberg reports

Big pharma's multiple looming patent cliffs: What to know
BMY

Yahoo Finance Video

a month ago

Big pharma's multiple looming patent cliffs: What to know

Share on Social Networks: